
Syntax
Syntax Bio is a synthetic biology company programming the next generation of stem cell-derived therapies and organoids.
$14.4M ·
Source: fundraisingfox.com
Funding history ↓Signals
Website registeredJan 2, 2024 (2 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Round | $14.4M | — | fundraisingfox.com |
Timeline
- Website created
Founders and team
- DDDoug Doerfler Founder, CEO, Board Advisorsource: syntax-bio.com
BM
Brad Merrill Co-Founder, Head of Innovationsource: syntax-bio.comNB
Niko Balanis Co-Founder, Chief Technology OfficerLinkedIn · source: syntax-bio.com- RCRyan Clarke Co-Founder, Chief Scientific Officersource: syntax-bio.com
Companies like Syntax
IImmumem TherapeuticsPre Seed · May 2026
TT-Knife$110M Series B+ · Aug 2021
BBioCardia$4.4M · Jun 2026
HheXem bio$2M Seed · Sep 2026
CClaris Bio$118M Series B+ · Jul 2026
SStemSight$2.3M Seed · Feb 2025
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/syntax (get a free API key).